ASTRAZEN6,843.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹17,108 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ASTRAZEN
FY26
SANOFICONR
FY26
PGHL
FY27
SANOFI
FY25
Peer
Median
Valuation — at last close
P/E91.23×40.09×93.84×17.33×40.09× +128%
P/B19.60×25.04×16.76×8.31×16.76× +17%
EV/EBITDA63.58×29.90×88.19×13.99×29.90× +113%
Market Cap₹17,108 Cr₹9,614 Cr₹9,022 Cr₹7,153 Cr₹9,022 Cr +90%
Growth
Revenue CAGR 3Y31.40%-33.37%-33.37% +194%
Revenue CAGR 5Y22.84%-18.46%-18.46% +224%
Net Income CAGR 3Y23.61%-25.17%-25.17% +194%
Revenue YoY (latest Q)29.73%6.70%7.37%-25.80%6.70% +344%
Net Income YoY (latest Q)-32.06%13.34%45.29%-33.70%13.34% -340%
Profitability
EBITDA Margin11.51%35.18%27.38%24.38%27.38% -58%
Net Income Margin8.24%27.33%26.44%20.53%26.44% -69%
Return on Common Equity21.49%62.53%17.86%48.02%48.02% -55%
Return on Capital Employed23.18%71.02%16.26%50.87%50.87% -54%
Return on Assets9.43%43.89%12.10%25.64%25.64% -63%
Credit & Quality
Total Debt/Equity0.00×0.00×0.00×0.00×0.00×
Interest Coverage51.99×148.65×668.43×302.73×302.73× -83%
Scale — latest FY
Revenue / Total Income₹2,276 Cr₹878 Cr₹364 Cr₹2,013 Cr₹878 Cr +159%
Net Income₹188 Cr₹240 Cr₹96.2 Cr₹413 Cr₹240 Cr -22%
Total Assets₹1,989 Cr₹547 Cr₹1,612 Cr₹1,079 Cr +84%
EPS₹75.01₹104.27₹57.92₹179.46₹104.27 -28%
Book Value per Share₹349.12₹166.96₹324.24₹374.17₹324.24 +8%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.